SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath is drawing attention after securing an order for more than 50,000 optical assemblies for drone cameras from an unnamed defense customer. Traders view it as a sign of counter-drone demand, though speculation that the customer is Leonardo DRS remains unconfirmed, and some investors remain cautious amid share-price weakness and upcoming earnings.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins choppy trading around the eight-cent area, including repeated slips below that level alongside weakness in other crypto and meme coins, dominates the discussion. Traders are split between expecting further downside and buying the dips or holding for a recovery, with no clear DOGE-specific catalyst emerging.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Traders are focused on Middle East LNG supply disruptions, including reported damage to Qatars export infrastructure and risks around the Strait of Hormuz, which they see as a potential long-term tailwind for U.S. LNG exporters such as NextDecade. The bullish view is tempered by concerns that Rio Grande LNG is still under construction and NEXT may not produce LNG until 2027, leaving execution, financing, and timing risks before it can benefit directly.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Discussion centers on Zebecs payroll and payments expansion, particularly its MoneyGram/Stellar connection and reported European and Robinhood Chain integrations, which bullish traders see as signs of growing adoption. Others argue that partnerships and reported business metrics have yet to translate into stronger, sustained demand for ZBCN, and complain that the tokens price remains weak.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BAT is drawing attention after a sharp rally alongside strength in other altcoins, with traders focused on whether technical momentum can sustain a breakout. Some see healthy consolidation and another leg higher, while others expect profit-taking or a pullback; no specific token catalyst is clearly confirmed.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

AMP is drawing attention after a sharp rally and volume surge, with traders noting its strength amid broader crypto weakness and debating whether the move can hold or will fade like previous pumps. Some bullish posts point to Flexa payments and Anvil collateral infrastructure as longer-term potential, but no single confirmed announcement is driving the discussion.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile Dow moves and its relative performance versus the Nasdaq and S&P, with traders split between crash warnings and bullish dip-buying. Fed and interest-rate concerns, rising yields, and oil-related geopolitical risks recur as market explanations, but no single catalyst dominates.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to a fresh 52-week high, with traders pointing to call-heavy options activity, short-covering potential and anticipation of Q3 results. Buyout speculationparticularly around Sanofiis prominent, but others see the move as pre-earnings positioning tied to BRIUMVIs growth and stress that no deal has been confirmed.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as the equal-weight S&P 500 has outperformed cap-weighted indexes amid weakness in mega-cap tech, with traders viewing the move as a rotation and broader market participation. Some see the strength and recent highs as a healthier rally, while others question whether breadth can hold or warn that the divergence may signal trouble.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today

AbbVies better-than-expected third-quarter results and raised full-year outlook are driving discussion, with traders highlighting growth in its immunology portfolio, particularly Skyrizi and Rinvoq. Many view the results positively, while some debate whether the stocks run-up leaves room for profit-taking.

Is AbbVie a Buy After Its Latest Earnings Report?

Key PointsAdjusted EPS nearly doubled, but most of that comes from last year's big research-deal charge, and underlying growth was closer to 17...

Equity

LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook.

AbbVie Raises 2026 Outlook, Boosts Dividend

AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.read more...

ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View

AbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.

AbbVie Q3 2026 Earnings Call Transcript

AbbVie (NYSE:ABBV) reported third-quarter financial results on Friday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...

Pre-Markets Spooked on Questions Regarding AI, Oil Prices

Led by the Nasdaq shedding another -2.5% (-750 points) ahead of the open, the stock market is looking at a down week of trading.

Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of +2.14% and +0.20%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

AbbVie Reports Third-Quarter 2026 Financial Results

AbbVie Reports Third-Quarter 2026 Financial Results AbbVie Reports Third-Quarter 2026 Financial ResultsPR NewswireNORTH CHICAGO, Ill., Oct. 30, 2026 Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over...

ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test

ExxonMobil headlines Friday's reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics, Regeneronread more...

$ABBV Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $3.82 up 105.38% YoY
• Reported revenue of $17.4B up 10.32% YoY
• AbbVie raised 2026 adjusted diluted EPS guidance from $13.76 - $13.96 to $13.95 - $13.99, including an unfavorable $0.69 per share impact related to acquired IPR&amp;D and milestones expense incurred year-to-date through Q3 2026.

Stocktwits

Abbvie Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $3.82 up 105.38% YoY
• Reported revenue of $17.4B up 10.32% YoY
• AbbVie raised 2026 adjusted diluted EPS guidance from $13.76 - $13.96 to $13.95 - $13.99, including an unfavorable $0.69 per share impact related to acquired IPR&D and milestones expense incurred year-to-date through Q3 2026.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $3.82 up 105.38% YoY
• Reported revenue of $17.4B up 10.32% YoY
• AbbVie raised 2026 adjusted diluted EPS guidance from $13.76 - $13.96 to $13.95 - $13.99, including an unfavorable $0.69 per share impact related to acquired IPR&D and milestones expense incurred year-to-date through Q3 2026.

AbbVie reported lower Humira and Imbruvica revenues, oncology revenue growth of 0.8%, declining aesthetics and Juvederm revenues, and identified competition, research and development, and drug-pricing risks.

AbbVie recorded growth in immunology and neuroscience revenues, completed the Apogee acquisition to deepen its immunology pipeline, and reported FDA approval of Skyrizi subcutaneous induction for Crohn's disease.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Neutral Sentiment

<ul class="summary-bullets"><li>UBS said Lilly’s underlying momentum and a higher Q4 growth run rate could potentially make current estimates appear too conservative.</li><li>AbbVie’s Q3 revenue rose 10.3% to $17.40 billion, driven by over 16% growth in its immunology business.</li><li>AbbVie raised its FY 2026 revenue forecast to $67.8 billion from $67.6 billion and adjusted EPS guidance to $13.95 - $13.99 from $13.76 - $13.96.</li></ul>Shares of Eli Lilly (LLY) and AbbVie (ABBV) climbed to new record highs on Friday after the pharmaceutical behemoths reported stronger-than-expected third-quarter earnings and raised their full-year 2026 outlooks.<a class="mention" data-mention="$LLY" data-symbol-id="LLY" href="https://stocktwits.com/symbol/LLY" target="_blank">LLY stock</a> was up 3.5% at the time of writing, extending its gains to a fifth straight session. It is on track to post its biggest monthly gains since November 2025. Meanwhile, <a href="https://stocktwits.com/symbol/ABBV">ABBV shares</a> rose 1.6%.<h2 class="st-heading-2">Wall Street Sees Upside For LLY After Q3 Earnings Beat</h2>Analysts turned bullish on Eli Lilly (LLY) on Friday, betting on its obesity-drug leadership and expanding pipeline. Scotiabank raised its target to $1,605 from $1,300 and held an ‘Outperform’ rating, expecting Lilly to maintain its obesity-market dominance through ‘next-generation products’ and acquisitions.Truist lifted its target to $1,612 from $1,376, and maintained a ‘Buy’ rating. The firm said Lilly currently has only about 10% market penetration in obesity, and expansion of its incretin franchise and pipeline will cement its dominance in “diabesity” for years to come.On Thursday, Lilly <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-ceo-cites-growth-beyond-weight-loss-in-oncology-immunology-as-key-to-fy-2026-outlook-raise-lly-stock/cZUQZzqR9bs">reported</a> a 39% increase in Q3 revenue to $24.4 billion, while adjusted earnings rose 7% to $7.48 per share. Mounjaro sales surged 65% to $10.72 billion, while Zepbound revenue rose 49% to $5.35 billion. Lilly also raised its 2026 revenue outlook to $91 billion-$92 billion from $85 billion-$87 billion. However, the company trimmed its bottom-line guidance to $35-$36 per share from $35.5-$36.5 per share.UBS said Lilly’s underlying momentum and a higher Q4 growth run rate could potentially make current estimates appear too conservative.Retail sentiment surrounding LLY on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier. The stock has gained more than 31% so far in 2026.<h2 class="st-heading-2">AbbVie Raises FY26 Outlook</h2>AbbVie reported better-than-expected Q3 earnings on Friday, driven by strong growth in its immunology business.Revenue rose 10.3% to $17.40 billion, beating Wall Street’s estimates of $17.34 billion, according to Fiscal.ai. Adjusted earnings more than doubled to $3.82 per share, exceeding consensus estimates of $3.77 per share.Immunology revenue increased 16.3%, with Skyrizi, its autoimmune drug for psoriatic arthritis and Crohn’s disease, among others, generating $5.78 billion. Rinvoq, prescribed for inflammatory conditions including rheumatoid arthritis and eczema, saw sales surge nearly 24%.AbbVie also raised its FY 2026 revenue forecast to $67.8 billion from $67.6 billion and adjusted EPS guidance to $13.95 - $13.99 from $13.76 - $13.96.In a call with analysts, chief scientific officer Roopal Thakkar said the company is interested in expanding its obesity-treatment pipeline, according to The Fly.Meanwhile, retail sentiment for ABBV on Stocktwits remained ‘neutral’ over the past 24 hours. The stock has gained about 29% in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-spacex-merger-could-face-the-biggest-regulatory-risk-in-china-bof-a-warns/cZULbGrR9cb">Tesla-SpaceX Merger Could Face The Biggest Regulatory Risk In China, BofA Warns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Abbvie Pharma logo seen on screen in the background with pills and a medical vial with syringe, seen in this photo illustration, on 14 August 2023 in Brussels, Belgium. (Photo Illustration by Jonathan Raa/NurPhoto via Getty Images)

Lilly(Eli) & Co

Roundhill GLP-1 & Weight Loss ETF

Track ABBV stock price, charts, news and real-time market activity on Stocktwits. Join the ABBV message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AbbVie Inc stock.

ABBV Stock Price Today - Abbvie Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

ABBV News